The History of Clinical Islet Transplantation in Japan.
Taihei ItoTakashi KenmochiKei KuriharaNaohiro AidaPublished in: Journal of clinical medicine (2022)
Islet transplantation shows the promise of being capable of relieving glucose instability and improving QOL of patients with type 1 diabetes that cannot be controlled due to severe hypoglycemia unawareness. In Japan, following the first human islet isolation from a donor after cardiac death in 2003 and the first clinical islet transplantation in 2004, islet transplantation was performed for the improvement of type 1 diabetes as a single-center trial in several centers. Although it was discontinued due to the possibility of contamination of collagenase by bovine brain component in 2007, the phase II clinical trial of islet transplantation started using ATG induction and a TNF-α inhibition protocol in 2012. The primary endpoints of this trial were the proportion of patients with HbA1c < 7.4% and freedom from severe hypoglycemic events at one year after the first islet cell infusion. In an interim analysis, this endpoint was achieved in 75% of cases. In April 2020, clinical islet transplantation was finally covered by health insurance in Japan, thanks to these outcomes. We herein introduce more than 20 years of history of clinical islet transplantation in Japan.
Keyphrases
- phase ii
- clinical trial
- cell therapy
- health insurance
- phase iii
- open label
- study protocol
- type diabetes
- rheumatoid arthritis
- endothelial cells
- healthcare
- early onset
- low dose
- stem cells
- adipose tissue
- left ventricular
- metabolic syndrome
- multiple sclerosis
- single cell
- mesenchymal stem cells
- heavy metals
- blood glucose
- climate change
- double blind
- placebo controlled
- big data
- cerebral ischemia
- data analysis